Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.

Abstract

Several compounds that exhibit a therapeutic effect in experimental models of neurodegenerative diseases have been identified over recent years. Safe and effective drug delivery to the central nervous system is still one of the main obstacles in translating these experimental strategies into clinical therapies. Different approaches have been developed to enable drug delivery in close proximity to the desired site of action. In this review, we describe biodegradable polymeric systems as drug carriers in models of neurodegenerative diseases. Biomaterials described for intracerebral drug delivery are well tolerated by the host tissue and do not exhibit cytotoxic, immunologic, carcinogenic or teratogenic effects even after chronic exposure. Behavioral improvement and normalization of brain morphology have been observed following treatment using such biomaterials in animal models of Parkinson's, Alzheimer's and Huntington's diseases. Application of these devices for neuroactive drugs is still restricted due to the relatively small volume of tissue exposed to active compound. Further development of polymeric drug delivery systems will require that larger volumes of brain tissue are targeted, with a controlled and sustained drug release that is carefully controlled so it does not cause damage to the surrounding tissue.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Neuronal Survival Unit, Department of Experimental Medical Science, BMC A10, 22 184 Lund, Sweden. natalija.popovic@med.lu.se

    Source

    International journal of pharmaceutics 314:2 2006 May 18 pg 120-6

    MeSH

    Alzheimer Disease
    Animals
    Brain
    Delayed-Action Preparations
    Diffusion
    Disease Models, Animal
    Drug Carriers
    Drug Stability
    Humans
    Huntington Disease
    Levodopa
    Microspheres
    Nerve Growth Factor
    Neurodegenerative Diseases
    Neuroprotective Agents
    Parkinsonian Disorders
    Polymers
    Solubility

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    16529886

    Citation

    Popovic, N, and P Brundin. "Therapeutic Potential of Controlled Drug Delivery Systems in Neurodegenerative Diseases." International Journal of Pharmaceutics, vol. 314, no. 2, 2006, pp. 120-6.
    Popovic N, Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int J Pharm. 2006;314(2):120-6.
    Popovic, N., & Brundin, P. (2006). Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. International Journal of Pharmaceutics, 314(2), pp. 120-6.
    Popovic N, Brundin P. Therapeutic Potential of Controlled Drug Delivery Systems in Neurodegenerative Diseases. Int J Pharm. 2006 May 18;314(2):120-6. PubMed PMID: 16529886.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. AU - Popovic,N, AU - Brundin,P, Y1 - 2006/03/10/ PY - 2005/07/01/received PY - 2005/09/09/accepted PY - 2006/3/15/pubmed PY - 2007/8/7/medline PY - 2006/3/15/entrez SP - 120 EP - 6 JF - International journal of pharmaceutics JO - Int J Pharm VL - 314 IS - 2 N2 - Several compounds that exhibit a therapeutic effect in experimental models of neurodegenerative diseases have been identified over recent years. Safe and effective drug delivery to the central nervous system is still one of the main obstacles in translating these experimental strategies into clinical therapies. Different approaches have been developed to enable drug delivery in close proximity to the desired site of action. In this review, we describe biodegradable polymeric systems as drug carriers in models of neurodegenerative diseases. Biomaterials described for intracerebral drug delivery are well tolerated by the host tissue and do not exhibit cytotoxic, immunologic, carcinogenic or teratogenic effects even after chronic exposure. Behavioral improvement and normalization of brain morphology have been observed following treatment using such biomaterials in animal models of Parkinson's, Alzheimer's and Huntington's diseases. Application of these devices for neuroactive drugs is still restricted due to the relatively small volume of tissue exposed to active compound. Further development of polymeric drug delivery systems will require that larger volumes of brain tissue are targeted, with a controlled and sustained drug release that is carefully controlled so it does not cause damage to the surrounding tissue. SN - 0378-5173 UR - https://www.unboundmedicine.com/medline/citation/16529886/Therapeutic_potential_of_controlled_drug_delivery_systems_in_neurodegenerative_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5173(06)00092-5 DB - PRIME DP - Unbound Medicine ER -